BASELINE CHARACTERISTICS OF THE ALIGN TRIAL: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF ATRASENTAN IN PATIENTS WITH IGAN

Back

E-Poster

https://storage.unitedwebnetwork.com/files/1099/e56c803abf913e316ec7b2d5eafe6b4d.pdf

Abstract Title

First Name *

Hiddo J. L.

Last Name *

Heerspink

Co-author 1

Meg Jardine meg.jardine@sydney.edu.au University of Sydney NHMRC Clinical Trials Centre Sydney

Co-author 2

Donald E. Kohan donald.kohan@hsc.utah.edu University of Utah Health Sciences Center Division of Nephrology Salt Lake City

Co-author 3

Richard A. Lafayette czar@stanford.edu Stanford University Stanford Glomerular Disease Center Stanford

Co-author 4

Adeera Levin ALevin@providencehealth.bc.ca The University of British Columbia Division of Nephrology Vancouver

Co-author 5

Adrian Liew draliew2@gmail.com Mount Elizabeth Novena Hospital Renal Medicine Singapore

Co-author 6

Hong Zhang hongzh@bjmu.edu.cn Peking University First Hospital Renal Division Beijing

Co-author 7

Todd Gray tgray@chinooktx.com Chinook Therapeutics, a Novartis Company Biostatistics Seattle

Co-author 8

Khushboo Sheth ksheth@chinooktx.com Chinook Therapeutics, a Novartis Company Clinical Development Seattle

Co-author 9

Marianne Camargo mcamargo@chinooktx.com Chinook Therapeutics, A Novartis Company Clinical Development Seattle

Co-author 10

Ronny Renfurm ronny.renfurm@novartis.com Novartis Pharma AG Cardio-Renal Metabolism Global Drug Development Basel

Co-author 11

Andrew King aking@chinooktx.com Chinook Therapeutics, A Novartis Company Research and Development Seattle

Co-author 12

Jonathan Barratt jb81@leicester.ac.uk University Hospitals of Leicester NHS Trust Department of Cardiovascular Sciences, Renal Medicine Leicester

Co-author 13

Co-author 14

Co-author 15